Bevacizumab tachyphylaxis

Ophthalmology. 2009 May;116(5):1016-7; author reply 1017. doi: 10.1016/j.ophtha.2009.01.029.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Drug Therapy, Combination
  • Exudates and Transudates
  • Humans
  • Injections
  • Macular Degeneration / diagnosis
  • Macular Degeneration / drug therapy*
  • Retina / pathology
  • Retreatment
  • Retrospective Studies
  • Tachyphylaxis*
  • Tomography, Optical Coherence
  • Triamcinolone Acetonide / therapeutic use*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Triamcinolone Acetonide